In vitro experiments have demonstrated that suppressing the expression of CBL-b can significantly enhance the function of T lymphocytes and their cytotoxic activity against prostate cancer cell lines, thus exerting a positive regulatory effect on anti-tumor immune responses (Zhou et al., 2014). This evidence concerns the gene CBLB and prostate cancer.